Curated News
By: NewsRamp Editorial Staff
September 28, 2026
Helix BioPharma Strengthens Board with Four New Directors
TLDR
- Helix BioPharma added four biotech leaders to its Board, gaining capital markets, clinical, and commercialization expertise to advance its oncology pipeline.
- Helix BioPharma appointed Karen Krumeich, Jamieson Bondarenko, Charmaine Lykins, and Dirk Brockstedt to its Board, with Krumeich as Chair, while three directors resigned.
- Helix BioPharma's new Board brings diverse expertise to develop therapies for difficult-to-treat cancers, potentially improving outcomes for underserved patients.
- Helix BioPharma's Board renewal includes leaders with experience at Karuna, Acadia, and RAPT Therapeutics, plus a Chair who is an angel investor.
Impact - Why it Matters
This board renewal signals a pivotal moment for Helix BioPharma as it advances its oncology pipeline. The addition of directors with deep expertise in biotechnology leadership, capital markets, and clinical development could enhance the company's ability to secure financing, navigate regulatory pathways, and execute on strategic objectives. For investors, the strengthened governance and independent oversight may increase confidence in Helix's ability to create long-term value, especially as it develops therapies for difficult-to-treat cancers with high unmet need. The reconstituted Audit Committee, entirely independent, further reinforces financial accountability. In a competitive oncology landscape, such governance upgrades are often a precursor to accelerated clinical progress and potential partnerships, making this news relevant to shareholders and the broader biotech community.
Summary
Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCF, FRANKFURT: HBP0), a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers, has announced a significant Board of Directors renewal effective September 28, 2026. The company appointed four new directors: Karen Krumeich, Jamieson Bondarenko, CFA, CMT, Charmaine Lykins, MBA, and Dirk Brockstedt, Ph.D. Ms. Krumeich has also been appointed Chair of the Board and Audit Committee. In a planned transition, Mr. Jacek Antas, Ms. Malgorzata Laube, and Mr. Jerzy Leszczynski have voluntarily resigned from the Board. This move is part of Helix’s ongoing efforts to strengthen governance with complementary expertise across biotechnology leadership, corporate governance, finance, scientific and clinical development, commercialization, and capital markets.
Thomas Mehrling, M.D., Ph.D., CEO of Helix BioPharma, expressed enthusiasm about the new appointments, stating, “Together, these Board members bring an exceptional breadth of complementary expertise... Their collective experience significantly strengthens our Board at an important stage in Helix’s evolution.” He also thanked the departing directors for their service. The new appointees bring impressive credentials: Karen Krumeich is a seasoned life sciences financial executive with CFO experience at several public and private companies; Jamieson Bondarenko is an active investor and capital markets executive; Charmaine Lykins is a biopharmaceutical commercial leader with over 30 years of experience; and Dr. Dirk Brockstedt is a biotechnology executive and scientist with deep expertise in immunology and oncology. Following these changes, the Board comprises six directors, four of whom are independent. The Audit Committee was reconstituted entirely of independent directors: Karen Krumeich as Chair, Zachary T. Stadnyk, and Jamieson Bondarenko.
Helix BioPharma is focused on developing therapies for underserved patient populations with difficult-to-treat cancers. Its pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate for non-small cell lung cancer (NSCLC), and includes pre-IND candidates LEUMUNA™ for post-transplant leukemia relapse and GEMCEDA™ for advanced solid tumors. The company’s shares are listed on the TSX, OTC Pink, and Frankfurt Stock Exchange. For more information, visit https://www.helixbiopharma.com/. The original release can be viewed on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Helix BioPharma Strengthens Board with Four New Directors
